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Abstract
Background: Vitamin D deficiency during pregnancy is common and is likely to be associated with metabolic
complications in the mother. The aim of this study was to assess the efficacy of two doses of vitamin D supplementation
during pregnancy on maternal and cord blood vitamin D status and metabolic and oxidative stress biomarkers.
Methods: The eligible pregnant women (n= 84) invited to participate in the study and randomly allocated to one of the
two supplementation groups (1000 IU/d vitamin D and 2000 IU/d).
Biochemical assessments of mothers including serum concentrations of 25(OH)D, calcium, phosphate, iPTH, fasting serum
sugar (FBS), insulin, triglyceride, total cholesterol, LDL-C, HDL-C, malondialdehyde (MDA) and total antioxidant capacity (TAC)
were done at the beginning and 34weeks of gestation. Cord blood serum concentrations of 25(OH)D, iPTH, MDA and TAC
were assessed at delivery as well. To determine the effects of vitamin D supplementation on metabolic markers 1-factor
repeated-measures analysis of variance (ANOVA) was used. Between groups comparisons was done by using Independent-
samples Student’s t-test or Mann-Whitney test. P< 0.05 was considered as significant.
Results: Supplementation with 1000 IU/d and 2000 IU/d vitamin D resulted in significant changes in vitamin D status over
pregnancy (24.01 ± 21.7, P< 0.001 in 1000 IU/d group and 46.7 ± 30.6 nmol/L, P< 0.001 in 2000 IU/d group). Daily intake of
2000 compared with 1000 IU/d tended to increase the serum concentration of HDL-C (10 ± 8.37, P< 0.001 in 1000 IU/d
group and 9.52 ± 11.39mg/dL, P< 0.001 in 2000 IU/d group). A significant decrement in serum concentration of iPTH
observed in both groups (− 4.18 ± 7.5, P= 0.002 in 1000 IU/d group and− 8.36 ± 14.17, P= 0.002 in 2000 IU/d group).
Conclusions: Supplementation with 2000 IU/d vitamin D as compared with 1000 IU/d, is more effective in promoting
vitamin D status and HDL-C serum concentration and in decreasing iPTH over pregnancy.
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Background
Physiologic alterations during pregnancy cause changes
in the concentrations of many circulating metabolites
and analytes including glucose, lipids and lipoproteins.
The extent of these changes highly depends on interac-
tions of dietary intake, genetic makeup and hormonal
milieu [1–3].
Among the modifiable factors affecting gestational
blood glucose and lipid alterations, nutrition has a cru-
cial role. Apart from proper gestational weight gain and
adhering to a healthy diet prior to and throughout preg-
nancy, vitamin D status of mother has attracted a huge
attention for some reasons [4, 5]. Several research
groups have scrutinized the relationship between vitamin
D deficiency and abnormal glucose homeostasis [6–10]
and lipid metabolism [11] in pregnancy. Furthermore,
some clinical trials have revealed that vitamin D supple-
mentation during pregnancy might improve the status of
lipid profile [12–14], glycemia [15], and parathyroid hor-
mone [16].
It is believed that certain level of oxidative stress (OS),
both placental and maternal, is necessary for a normal
pregnancy [17, 18]. However, pathological increment of
OS during pregnancy could have a role in development
of adverse pregnancy outcomes through damaging sus-
ceptible placenta [19, 20]. On the other hand, some
studies have revealed antioxidative properties of vitamin
D [21–23] which might be associated with certain meta-
bolic variables, notably blood glucose and lipids [24].
However, these effects of vitamin D during pregnancy
still need further elucidation.
High prevalence of vitamin D deficiency during pregnancy
is common in most countries of the world [25, 26], including
Iran [27, 28]. It is noteworthy that the Iran Ministry of
Health (IrMOH) communicated with all governmental
health centers to prescribe 1000 IU/d vitamin D supplement
to all pregnant women from the beginning of pregnancy.
However, the efficacy of supplementation with this dosage
(1000 IU/d) early in pregnancy has not yet been evaluated
and compared with that of 2000 IU/d, which has been more
efficient in improving vitamin D status and depressing cer-
tain inflammatory biomarkers, than 1000 IU/d [29]. We,
therefore, designed this clinical trial from the first trimester
of pregnancy to examine and compare the efficacy of these
two dosages of vitamin D (1000 IU/d and 2000 IU/d) on cer-
tain metabolic parameters including glycemic, lipidemic and
parathyroid hormone as well as OS status.
Methods
Study design
This study was a part of a larger project whose complete
protocol has been comprehensively described elsewhere
[30]. In an open-label randomized clinical trial, 84 preg-
nant women who met the inclusion criteria and were at-
tending the outpatient obstetric clinics of three hospitals
(with similar cultural, educational and economic status) in
Tehran between February 2017 and January 2018 were en-
rolled. This study adhered to CONSORT guidelines.
We calculated that a sample of 37 subjects in each
group would have 90% power to detect a change in means
of 25(OH)D of 0.75 of SD (assuming an effect size of
0.75). Based on the previous study [31], 0.75 of SD would
be 18 nmol/L.
Inclusion criteria were: 1) being at the first trimester
of pregnancy, 2) the absence of any clinical disease in-
cluding endocrine, cardiovascular, liver and kidney dis-
eases, 3) not taking vitamin D (> 600 IU/d) and/or
omega-3 supplements and/or steroids during the past 3
months, 4) the willingness to take part in the study.
Exclusion criteria were: 1) identified to have FBS > 92
mg/dL or blood pressure > 140/90 mmHg at the first
visit, 2) consuming omega-3 and/or extra vitamin D sup-
plement and/or other drugs that interfere with vitamin
D metabolism during the intervention period, 3) poor
compliance to the supplementation 4) unwillingness to
continue the intervention.
Those subjects who met the inclusion criteria were
randomly allocated to one of the two groups to take ei-
ther 1000 IU (one tablet)/d or 2000 IU (two tablets)/d
vitamin D from the first trimester till the end of preg-
nancy. Block randomization applied using 6 blocked
sizes of 4 to generate 21 randomized block allocations
for random allocation. All participants were allowed to
receive the common supplementation during pregnancy
(folic acid, iron and multivitamins providing < 600 IU/d
vitamin D). The vitamin D3 tablets were purchased from
Jalinous pharmaceutical company, Tehran, Iran.
All subjects were visited at first trimester and 34–36
week of gestation. At the first visit, demographic infor-
mation was collected from all participants. Adherence to
the determined supplementation regimen was evaluated
as described earlier [30]. Briefly, the participants were
asked to return the pills not consumed for any reason.
Meanwhile, they were contacted by telephone call every
week to check consumption of the supplements. The
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following equation was applied to assess the adherence
rate: (Number of pills dispensed − number of pills
remained)/(prescribed number of pills per day × number
of days between 2 visits. Accordingly, the participants di-
vided into three groups including strictly (> = 80%),
moderately (50–80%) and poorly (≤50%) compliant.
Those participants with poor compliance (consumption
of less than 50% of the prescribed vitamin D supple-
ments in a month) were excluded from the study. The
strictly and moderately compliant subgroups supposed
to be separately analyzed.
Anthropometric and blood pressure measurements
have been described elsewhere [30].
To determine the mean score of sunlight exposure, the
information about the amount of time spent outdoors
each day during previous week were collected by using the
weekly sunlight exposure recall questionnaire [32]. Then
the score of time outdoors (score 0 for ≤5min; score 1 for
5–30min; score 2 for ≥30min) and the score of the
amount of skin exposure (score 1 for face and hands only;
score 2 for face, hands, and arms; score 3 for face, hands,
and legs; score 4 for almost the entire body) were multi-
plied to calculate sunlight exposure score. The sunlight
exposure score range is assumed to be 0 to 56 [32].
To assess the level of physical activity, an Iranian ver-
sion of the International Physical Activity Questionnaire
(IPAQ) was used [33].
A 24-h recall questionnaire was used to assess the
amount of energy, macronutrient (protein, carbohydrate
and fat) and micronutrient intake (vitamin A, D, E, K, C,
calcium, iron, zinc) for 2 days (a week day and a week-
end day), the mean of which was considered as the indi-
vidual’s dietary intake. The analysis of questionnaires
data was done using Nutritionist IV software (First Data-
bank, San Bruno, CA, USA) modified for Iranian foods.
The protocol of this study was approved by the Ethics
Committee of Shahid Beheshti University of Medical
Sciences. This trial is registered at clinicaltrials.gov
(NCT03308487).
Biochemical investigations
Ten mL of 12–14 h fasting venous blood and spot urine
samples were collected from all participants at first tri-
mester and 34–36 weeks of gestation. In addition, 5 mL
of cord blood samples were collected at the time of de-
livery. All blood and urine samples were transferred to
the Laboratory of Nutrition Research, NNFTRI, in a cold
box. Blood samples were centrifuged in less than 2 h at
800 g at room temperature for 30 min. The separated
sera and urine samples were aliquoted and kept at −
80 °C freezer for further analyses. Sera from cord blood
samples were handled similarly.
Fasting serum glucose, lipid profile components, cal-
cium and phosphorous were assayed on the same day of
blood sampling using commercial kits (all from Pars-
Azmoon, Tehran, Iran) and an auto-analyzer (Selecta E;
Vitalab, Holliston, Netherlands).
Fasting serum insulin was measured by using an en-
zyme immunoassay (EIA) kit (DiaPlus inc., Canada) with
intra- and inter-assay coefficient of variations (CVs) of
4.9 and 8%, respectively, based on manufacturer’s data.
HOMA-IR which calculated based on suggested for-
mulas [34], was used to assess insulin resistance.
The concentrations of 25(OH)D and iPTH in all
serum samples were determined using commercial
enzyme-immunoassay (EIA) kits (both from EUROIM-
MUN, Leubeck, Germany). For 25(OH)D assay kit, the
inter-assay CVs ranged from 7 to 8.6- and intra-assay
CVs ranged from 3.2 to 6.9% whereas for iPTH intra-
and inter-assay CVs were 2.2–9.5% and 9.5–11%, re-
spectively, according to the manufacturer.
Urinary calcium and creatinine concentrations were
measured by commercial kits and an auto-analyzer. The
proportion of urinary calcium to creatinine concentra-
tions in the spot urine samples was used to determine
the possible effects of vitamin D supplementation on
urinary calcium excretion.
To evaluate OS, serum concentrations of malondialde-
hyde (MDA) as well as total antioxidant capacity were
determined. MDA assay was performed using thiobarbi-
turic acid reacting substances (TBARS), as previously de-
scribed [29]. To determine total antioxidant capacity
(TAC), the ability of serum antioxidants to inhibit 2,2ˊ-
azino di-(3-ethylbenzthiazoline sulfonate; ABTS) oxida-
tion was compared with that of bovine serum albumin,
as the standard [35].
Statistical analysis
To check normal distribution of continuous variables the
histogram and Kolmogorov-Smirnov test were applied.
The continuous data which normally distributed shown
as mean and standard deviation (SD) and categorical data
presented as frequency or percentage (%). Repeated-
measures ANOVA was used to determine the effect of
vitamin D supplementation on metabolic markers. In this
analysis, the treatment (2000 IU/d vitamin D vs. 1000 IU/d
vitamin D) and time (with 2 time points including baseline
and week 34 of the intervention) were considered as “be-
tween-subject factor” and “within-subject factor” respect-
ively. For between groups comparison, Independent-
samples Student’s t-test or Mann-Whitney test was used.
Either Pearson (r) or Spearman (rs) equations were applied
to assess the correlations between variables. The signifi-
cant level was P < 0.05.
Results
A total of 84 pregnant women were enrolled in the study
between February and June 2017. However, 73 subjects
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(n = 37 from group 1000 IU/d and n = 36 from group
2000 IU/d) completed the intervention. Losses and ex-
clusions were due to some reasons including miscar-
riage, preterm delivery, and unwillingness to continue
the participation (Fig. 1). Follow up period lasted till
January 2018.
In this study 2 subjects (about 5%) from 2000 IU/d
group had poor compliance and were excluded from the
study. The mean adherence percent among those who
continued the study were 93.7 and 90.4% in 1000 IU/d
and 2000 IU/d groups respectively. It is necessary to
mention that all participants who completed the study
were belonged to the strictly compliant subgroup.
Therefore, the study was out of moderately compliant
subgroup.
The baseline characteristics, sun exposure score and
physical activity level of the participants, duration of
intervention, number (percent) of participants who have
received routine supplementation and season of year at
the first visit have been shown in Table 1.
Vitamin D deficiency/insufficiency was found in 83.8
and 86.2% of the subjects in 1000 IU/d group and 2000
IU/d groups, respectively (Table 3).
The increment of the 25(OH)D was significantly
higher in response to vitamin D supplementation with
the dose of 2000 IU/d compared with 1000 IU/d (Ta-
bles 2 and 3). No significant between groups difference
was found in the cord blood concentration of 25(OH)D
(Table 4). The cord blood serum concentrations of
25(OH) D had a significant positive correlation with the
maternal one at third trimester (r = 0.38, P = 0.02).
Within- or between-group changes of FBS, serum in-
sulin, HOMA-IR were not significant. Compared with
the baseline values the concentration of TC, TG, LDL-C
and HDL-C increased significantly in both groups. How-
ever, between group changes were not significant
(Table 2). A small but statistically significant decrease in
serum calcium concentrations at late pregnancy was ob-
served in both groups (P < 0.001), although the values
remained in normal range. However the between-group
difference was not significant (P-interaction = 0.51).
Serum phosphate concentration did not differ over preg-
nancy in both groups (P-interaction = 0.21).
Final serum concentrations of iPTH in both groups de-
creased late in pregnancy (P < 0.05) but the difference be-
tween groups was not significant (Table 2). The cord
blood concentration of iPTH was not significantly differ-
ent between groups, either (Table 4). A significant nega-
tive correlation was found between serum concentrations
of 25(OH)D and iPTH (r = − 0.35, P = 0.003). The correl-
ation between mothers’ and cord blood serum concentra-
tion of iPTH was not significant (r = 0.19, P = 0.32).
The biomarkers of OS (MDA and TAC) did not
change significantly over pregnancy in any of the groups
(Table 2). Accordingly, cord blood MDA and TAC did
not show any significant between-group changes, either
(Table 4).
Initial and final dietary data showed no significant be-
tween group differences (Table 5).
Discussion
We found a relatively high proportion of vitamin D defi-
ciency and insufficiency among study participants at first
trimester of pregnancy. This finding is consistent with
what has been reported by several studies about the per-
centage of vitamin D deficiency among Iranian pregnant
women [27].
In addition, taking 2000 IU/d vitamin D3 for 24 weeks
improved vitamin D status more effectively than taking
1000 IU/d. This finding was compatible with that of other
trials examined the efficacy of similar doses [37–39].
Sufficient concentrations of cord blood 25(OH)D (> 75
nmol/L) were observed in both groups with no significant
between-group difference. Along the same line of evi-
dence, the daily intake of 2000–4000 IU vitamin D3
among women from 12 to 16- weeks of gestation until de-
livery prevented neonatal vitamin D deficiency [40].
Our study showed no association between vitamin D
supplementation and parameters of glucose homeostasis
including FBS, insulin and HOMA-IR during pregnancy.
In agreement with our findings, some studies failed to
show any beneficial effects of vitamin D supplementa-
tion on glycemic status of pregnant women [7, 8, 41,
42]. The results of some cohort studies showed that the
concentrations of circulating 25(OH)D might not be a
contributing factor for development of GDM in women
with a low risk for GDM [9, 43]. On the contrary, the re-
sults of a clinical trial showed that co-administration of
1000 mg calcium per day + 50,000 IU vitamin D every 3
weeks for 6 weeks to pregnant women with GDM could
improve glycemic status [44]. The effect of vitamin D
supplementation on glycemic status has been attributed
to its involvement in insulin secretion through its effect
on the regulation of serum calcium which in turn affects
pancreatic β cell function [45]. The observed inconsist-
ency might be due to the differences in doses and dur-
ation of vitamin D supplementation and the lack of
calcium co-supplementation and the fact that in our
study, vitamin D3 was administered to healthy pregnant
women with normal values of glycemic status.
We found a significant increase in serum concentra-
tions of lipid profile components including TG, total
cholesterol, HDL-C and LDL-C from beginning to the
late pregnancy in both groups, but the differences were
not significant between groups. During pregnancy along
with increasing gestational age the levels of lipid profile
increase most probably due to hormonal and metabolic
changes as a normal physiologic phenomena [46–49].
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The normal ranges of TG, TC, LDL-C, HDL-C during
third trimester of pregnancy suggested to be 131–453,
219–349, 101–224 and 48–87mg/dL respectively [50–
52]. Nevertheless, the importance of changes of blood
lipid metabolism during pregnancy pertains to its poten-
tial effect on perinatal morbidity and mortality. It has
been reported that dyslipidemia in pregnancy associated
with preeclampsia, GDM, preterm delivery and cardio-
vascular disease in the future [47]. Based on some evi-
dence, vitamin D deficiency during early pregnancy
associated with more unfavorable changes of lipid profile
[53, 54]. Therefore, it is assumed that vitamin D correc-
tion could have a beneficial effect on lipids during preg-
nancy. Asemi, et al. conducted a randomized, double-
Fig. 1 Flow diagram of the study
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blind, placebo-controlled clinical trial in 57 women with
GDM that received 50,000 IU vitamin D at baseline and
at day 21 of the intervention and those in the placebo
group received 2 placebos at the same times. Based on
the results, vitamin D supplementation resulted in in-
creased serum 25-hydroxyvitamin D concentrations
compared with placebo and a significant reduction in
concentrations of total cholesterol and LDL-C [55]. In
another study, supplementation of vitamin D among
GDM cases showed no positive effect on lipid profiles
compared with placebo. Although, serum concentration
of total cholesterol and LDL-C had a significant incre-
ment in the placebo group [56]. Inconsistently, the re-
sults of a trial among pregnant women, who were prone
to pre-eclampsia, revealed that supplementation of 50,
000 IU vitamin D, every 2 weeks from gestational age
of 20 to 32 weeks, in comparison to placebo, associ-
ated with increased level of HDL-C concentrations
[57]. The possible effect of vitamin D on lipid metab-
olism could be in part explained by decreased synthe-
sis and secretion of TG in liver and also
transformation of cholesterol into bile acids and sub-
sequently reduced level of cholesterol [58].
In the present study due to the lack of control group
we were unable to detect the effect of vitamin D supple-
mentation on the lipid profile. However, we found that
the effect of vitamin D supplementation with two doses
of 1000 IU/d and 2000 IU/d on the lipid profile during
Table 1 Baseline characteristics of subjectsa
Characteristic Group 1 (1000 IU/d)
n1 = 37
Group 2 (2000 IU/d)
n2 = 36
p value 2
Age, year 27.94 ± 5.60 27.41 ± 5.15 0.80
Gestational age at enrollment, week 10.39 ± 1.69 10.08 ± 2.17 0.77
Gestational age at delivery (week) 38.79 ± 1.65 39.91 ± 5.78 0.57
Weight gain at end of pregnancy (kg) 10.82 ± 5.21 12.01 ± 5.94 0.38
Weekly sunlight exposure score at enrollment 2.63 ± 2.08 1.97 ± 1.67 0.14
Weekly sunlight exposure score at last visit 1.70 ± 1.65 1.21 ± 1.15 0.17
Sunscreen use, n (%) 11 (30.4) 13 (36.9) 0.49
Physical activity at enrollment, n (%) 0.37
Low 29 (78.4) 28 (77.8)
Moderate 8 (21.6) 6 (16.7(
High 0 (0.0) 2 (5.6)
Physical activity at last visit, n (%) 0.59
Low 32 (86.5) 29 (80.6)
Moderate 5 (13.5) 6 (16.7)
High 0 (0.0) 1 (2.8)
Duration of intervention, n (%) 0.87
24 wk 11 (29.72) 10 (27.77)
25 wk 9 (24.32) 11 (30.55)
26 wk 6 (16.21) 7 (19.44)
27 wk 7 (18.91) 5 (13.88)
28 wk 4 (10.81) 3 (8.33)
Season at first visit, n (%) 0.89
Winter 14 (37.6) 16 (44.4)
Spring 23 (62.1) 20 (55.5)
Routine supplementationa, n (%)
Multivitamin 25 (67.5) 22 (61.1) 0.52
Folic acid 29 (78.37) 25 (69.44) 0.37
Iron 21 (56.75) 22 (61.11) 0.55
adata are expressed as mean ± SD and the distribution between groups expressed as n (%)
2t test and χ2 test were used to compare baseline characteristics
BMI Body mass index
aThe participants started to intake routine supplementation late in the fourth month of pregnancy
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pregnancy were not different. Future studies with higher
and safe doses of vitamin D supplementation may pro-
vide better explanations. The present study detected a
significant reduction in maternal serum iPTH concentra-
tion in both groups at the end of pregnancy, and a nega-
tive correlation between serum concentrations of
25(OH)D and iPTH. In agreement with our study re-
sults, an interventional study of three treatment groups
(400, 2000 or 4000 IU vitamin D3/day) from 12 weeks of
gestation until delivery, showed that the circulating PTH
of African American group had inverse correlation with
circulating 25(OH)D levels [59]. Okonofua et al., found
an inverse correlation between serum 25(OH)D and
PTH concentrations in the maternal serum but the in-
verse relationship disappeared when the ethnicity of
women was considered separately [60].
We found no correlation between mothers’ sera and
cord blood concentrations of iPTH or cord blood





















FBS (mg/dl) 74.70 ± 7.51 75.59 ± 6.98 0.89 ± 11.06 78.41 77.55 −0.86 ± 10.91 0.99 0.054 0.49
Insulin (mU/L) 7.97 ± 4.85 8.82 ± 5.47 0.85 ± 6.15 7.95 ± 5.96 10.40 ± 9.31 2.44 ± 10.28 0.11 0.53 0.44
HOMA_IR 1.45 ± 0.85 1.52 ± 1.21 0.21 ± 1.23 1.66 ± 1.11 2.03 ± 1.84 0.50 ± 2.03 0.08 0.37 0.47




131.19 ± 58.16 <
0.001
0.44 0.26




70.22 ± 35 <
0.001
0.49 0.84




9.52 ± 11.39 <
0.001
0.36 0.84




34.45 ± 27.39 <
0.001
0.86 0.74
LDL/HDL-C 1.58 ± 0.36 1.90 ± 0.44* 0.31 ± 0.44 1.56 ± 0.45 1.91 ± 0.46* 0.35 ± 0.47 <
0.001
0.92 0.76
TC/HDL-C 2.97 ± 0.44 3.71 ± 0.49* 0.73 ± 0.51 2.93 ± 0.55 3.67 ± 0.63* 0.73 ± 0.52 <
0.001
0.68 0.99
Calcium (mg/dl) 9.47 ± 0.38 8.97 ± 0.37* −0.5 ± 0.41 9.45 ± 0.39 9.01 ± 0.32* −0.43 ± 0.45 <
0.001
0.88 0.51
Phosphate (mg/dl) 4.37 ± 0.45 4.63 ± 1.0 0.26 ± 1.06 4.45 ± 0.62 4.45 ± 0.49 0.0 ± 0.69 0.21 0.67 0.21
iPTH (pg/ml) 17.96 ± 10.60 13.78 ± 7.05* −4.18 ± 7.5 23.51 ±
15.77
15.15 ± 7.68* −8.36 ± 14.17 <
0.001
0.11 0.13
MDA (nmol/mL) 21.17 ± 8.13 17.6 ± 8.7 −1.64 ± 10.42 18.87 ± 8.37 18.17 ± 8.07 1.9 ± 8.36 0.52 0.46 0.26
TAC (g/dL BSA
equivalent)
2.99 ± 0.37 2.79 ± 0.58 −0.19 ± 0.67 2.84 ± 0.55 2.78 ± 0.45 −0.06 ± 0.62 0.18 0.51 0.50
aAll values are expressed as means±SD (standard deviation)
2Resulted from 1-factor repeated measures ANOVA
*different from baseline, p < 0.05
**difference of changes between groups, P-interaction< 0.05
bTime×Group: Time means from the first to the last visit of intervention and group means comparison between the two groups of intervention
25(OH)D3 25-hydroxyvitamin D3, FBS fasting serum glucose, TC total cholesterol, TG triglycerides, LDL low-density lipoprotein, HDL high-density lipoprotein, iPTH
intact parathyroid hormone, MDA malondialdehyde, TAC total antioxidant capacity, HOMA-IR homeostasis model assessment of insulin resistance
Table 3 Comparison of vitamin D status based on serum concentration of 25(OH)D between groups
Group Before intervention After intervention p
value1Deficient Insufficient Sufficient Deficient Insufficient Sufficient
1000 IU/day, n (%) 26 (70.3) 5 (13.5) 6 (16.2) 3 (8.1) 20 (54.1) 14 (37.8) 0.04
2000 IU/day, n (%) 20 (55.6) 11 (30.6) 5 (13.9) 2 (5.6) 10 (27.8) 24 (66.7)
Total, n (%) 46 (63) 16 (21.9) 11 (15.1) 5 (6.8) 30 (41.1) 38 (52.1)
1Denotes the significance of differences in the distribution of vitamin D categories between the 2 groups (chi-square test)
Deficiency is defined as < 50 nmol/L, insufficiency as 50–75 nmol/L, and sufficiency as > 75 nmol/L
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concentrations of 25(OH)D and iPTH. Similar to our
results, Bowyer et al. showed no correlation between
PTH in neonates and their mothers [61]. Considering
the importance of minerals for fetus bone develop-
ment, active transport of calcium occurs across the
placenta which subsequently suppresses PTH secre-
tion [62]. Hirota et al. have shown that there is a sig-
nificantly higher level of the parathyroid hormone-
related protein (PTHrp) in umbilical venous blood
than those in pregnant women at any trimester [63].
PTHrp has an important role in active transferring of
calcium from mother to the fetus, possibly via chan-
ging the expression of calbindin-D 9 k [64].
We found no significant changes in maternal serum
concentration of MDA and TAC at the end of inter-
vention in any of the two groups and also no signifi-
cant between-group difference of these biomarkers in
cord blood. Similar to our data the findings of a trial
showed that vitamin D supplementation had no effect
on OS biomarkers among pregnant women with
GDM [55]. However, there are some evidence that
support a positive association between TAC and vita-
min D status [41, 65]. The findings of a systematic
review of clinical trials among non-pregnant partici-
pants revealed that vitamin D only with doses of 100,
000–200,000 IU/month could have beneficial effect on
the OS parameters (decreases MDA levels and in-
creases GSH and TAC levels) [23]. One of these
mechanisms that explain the effect of vitamin D on
OS biomarkers is the role of vitamin D on the ex-
pression of Nrf2 which in turn increases the produc-
tion of anti-oxidant enzymes [66]. The lack of
changes in OS biomarkers in the present study might,
at least in part, be related to the applied doses of
vitamin D. Therefore, further studies with different
doses could clarify the role of vitamin D supplemen-
tation on the OS biomarkers in pregnant women.
One of the strength points of this randomized clinical
trial is that vitamin D supplementation was started early
in pregnancy and lasted until delivery. We also assessed
dietary intake, physical activity level and sun exposure to
find their possible confounding effects. Biochemical
markers were measured in cord blood samples for better
understanding of the effects of the intervention. None-
theless, some limitations must be acknowledged. We did
not have a placebo control group (no vitamin D intake
via supplements including multivitamin) due to ethical
issues. Yet, our participants were normo-glycemic and
normo-lipidemic and this might hamper the possible ef-
fects of the intervention. However, this precaution was
necessary as this trial was performed to help policy-
makers at the Iran Ministry of Health to decide on vita-
min D supplementation during pregnancy for the whole
country.
Conclusions
Supplementation with 2000 IU/d vitamin D had no more
beneficial effects on the studied biomarkers of glycemic,
lipidemic and OS status of the maternal and cord blood
than with 1000 IU/d. Nevertheless, supplementation with
2000 IU a day, compared with 1000 IU/d, was more ef-
fective in improving vitamin D status and lowering the
occurrence of suboptimal circulating calcidiol concentra-
tions during pregnancy.
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25 (OH)D (nmol/L) 84.04 ± 35.14 89.0 ± 25.27 0.64
Cord blood 25(OH)D, n (%) 0.23
< 50 nmol/l 3 (20) 0 (0.0)
50–75 nmol/l 4 (26.7) 7 (38.9)
> 75 nmol/l 8 (53.3) 11 (61.1)
iPTH (pg/ml) 4.53 ± 2.82 4.70 ± 2.95 0.87
MDA (nmol/mL) 20.33 ± 5.9 20.55 ± 9.43 0.91
TAC (g/dL BSA equivalent) 3.15 ± 0.97 3.36 ± 0.91 0.58
aAll values are expressed as means (SD, standard deviation)
2Denotes the significance between groups differences (independent t-test)
25(OH)D3 25-hydroxyvitamin D3, iPTH intact parathyroid hormone, MDA
malondialdehyde, TAC total antioxidant capacity
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